Does orphan drug legislation really answer the needs of patients?

被引：56

作者：

Haffner, Marlene E. ^{[1
]}

Torrent-Farnell, Josep ^{[2
]}

Maher, Paul D. ^{[2
]}

机构：

[1] Amgen Corp, Washington, DC 20004 USA

[2] US FDA, Off Orphan Prod Dev, Rockville, MD 20857 USA

来源：

LANCET | 2008年 / 371卷 / 9629期

关键词：

D O I：

10.1016/S0140-6736(08)60873-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2041 / 2044

页数：4

共 32 条

[21] Potential interactions of the orphan drug act and pharmacogenomics: A flood of orphan drugs and abuses? [J].

Loughnot, D .

AMERICAN JOURNAL OF LAW & MEDICINE, 2005, 31 (2-3) :365-380

[22]

LOVE J, BRIEF NOTE ABUSE ORP

[23] The Orphan Drug backlash [J].

Maeder, T .

SCIENTIFIC AMERICAN, 2003, 288 (05) :80-87

[24] Orphan drug designation and pharmacogenomics - Options and opportunities [J].

Maher, Paul D. ;

Haffer, Marlene .

BIODRUGS, 2006, 20 (02) :71-79

[25] Orphan products - pain relief for clinical development headaches [J].

Milne, CP .

NATURE BIOTECHNOLOGY, 2002, 20 (08) :780-784

[26]

Office of Orphan Products Development, LIST ORPH DES APPR

[27]

Rados Carol, 2003, FDA Consum, V37, P10

[28] The genetic tyrosinemias [J].

Scott, CR .

AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2006, 142C (02) :121-126

[29] ORPHAN DRUGS FOR THE THIRD-WORLD [J].

SIMON, HJ .

ANNALS OF INTERNAL MEDICINE, 1981, 95 (02) :231-232

[30]

SMITH A, ORPHAN BLOCKBUSTER B

← 1 2 3 4 →